Who makes Intermittent, short infusion Cefepime?

Intermittent, short infusion Cefepime is developed by The Alfred.

What development phase is Intermittent, short infusion Cefepime in?

Intermittent, short infusion Cefepime is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Intermittent, short infusion Cefepime

The Alfred · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Intermittent, short infusion Cefepime
Sponsor	The Alfred
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Intermittent, short infusion Cefepime CI brief — competitive landscape report
Intermittent, short infusion Cefepime updates RSS · CI watch RSS
The Alfred portfolio CI